| ID | 1060 |
| Name of the vaccine | Boostrix Polio |
| Microbe | Bacteria |
| Disease name | Pertussis (Whooping Cough) |
| Name of bacteria | Bordetella pertussis |
| Type of vaccine | Combination |
| Nucleic acid content | DNA |
| Age | From 4 years |
| Description of the vaccine | Combined diphtheria, tetanus, acellular pertussis and enhanced inactivated polio vaccine. |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2007 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative coccobacillus. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Single dose of 0.5 mL. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Booster vaccination against diphtheria, tetanus, pertussis and poliomyelitis. |
| Export | Marketing Authorisation Holder : GlaxoSmithKline (Thailand) Ltd. |
| Approval | Thailand FDA |
| Adjuvant | Aluminium hydroxide and aluminium phosphate |
| Repurposing | For tetanus, diphtheria and inactivated poliovirus. |
| Side effects of vaccine | Somnolence, injection site reactions, headache, malaise and fatigue. |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.moph.go.th/sites/drug/Summary/2C_14_50_NB_BOOSTRIX%20POLIO.pdf |
| Other name | NA |
| Additional Links | NA
|